TD Cowen Gives Buy Rating to Century Therapeutics – A Promising Player in Stem Cell Therapies
TD Cowen starts coverage on Century Therapeutics with a Buy rating, highlighting its lead stem cell therapy for type 1 diabetes and potential for long-term value as the pipeline grows.